Skip to main content

Advertisement

Table 1 Characteristics of the included studies

From: Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis

Author Year Country Number of patients Duration of follow-up Methods Staining patterns Cut off scores (high/low) T category (T0/T1/2/3/4) N category (P/N) Distant metastasis (M1/M0) State of CerbB-2 (P/N) Stata of ER (P/N) Stata of PR (P/N) 5-year OS rate 5-year DFS rate
Zhang [10] 2012 China 232 NA IHC Membrane or cytoplasm 5% (134/98) H:(0/48/86/0/0); L:(0/38/60/0/0) H:(70/64); L:(28/70) NA H:(82/52); L:(38/60) H:(52/82); L:(44/54) H:(44/90); L:(38/60)   
PARKER [11] 2012 USA 185 54 months Western blots Membrane and cytoplasm ≥7.5 F (37/148) H:(0/7/21/7/2); L:(2/21/82/24/18) H:(37/37); L:(148/148) NA H:(14/20); L:(39/91) H:(12/23); L:(51/97) H:(11/24); L:(45/103) H:57% (21/37) L:69% (102/148) H:53% (20/37) L:62% (92/148)
Hiller [12] 2011 USA 77 42 months Western blots Membrane and cytoplasm ≥6.6 F (22/55) LABC(NA) NA NA     H:50% (11/22) L:78% (43/55) H:41% (9/22) L:67% (37/55)
Chu [13] 2010 USA 101 59 months Western blots Membrane and cytoplasm ≥6.6 F (22/79) H:(0/8/11/3/0); L:(0/58/18/3/0) NA NA     H:81% (18/22) L:97% (77/79) H:79% (17/22) L:96% (76/79)
Liu [14] 2010 China 200 88 months TMA Cytoplasm Score ≥ 6 (110/90) H:(0/41/56/13/0); L:(0/27/50/13/0) H:(69/41); L:(31/59) NA H:(32/78); L:(15/75) H:(59/51); L:(41/49) H:(60/50); L:(39/51) H:68% (75/110) L:80% (72/90)  
Liu* [14] 2010 China 200 88 months TMA Nuclear Score ≥ 6 (113/87) H:(0/32/67/14/0); L:(0/36/39/12/0) H:(61/52); L:(39/48) NA H:(87/26); L:(21/66) H:(62/51); L:(38/49) H:(62/51); L:(37/50) H:63% (71/113) L:82% (71/87)  
Mizell [15] 2009 USA 115 53 months Western blots Membrane and cytoplasm ≥6.6 F (13/102) H:(0/2/10/0/1); L:(0/41/50/10/1) H:(6/7); L:(31/71) H:(5/8); L:(14/88) H:(0/13); L:(0/102) H:(2/11); L:(37/65) H:(2/11); L:(34/68) H:52% (7/13) L:86% (88/102) H:38% (5/13); L:74% (75/102)
ANDRE [16] 2009 USA 794 10 years IHC Membrane or cytoplasm 1% (92/702) H:≥3 (9/81); L: ≥3 (61/637) H:(40/51); L:(300/402) H:(28/64); L:(155/547) H:(10/79); L:(88/607) H:(41/36); L:(378/238)    
Yasuoka [17] 2008 Japan 113 5 years IHC Cytoplasmic Score ≥ 5 (56/57) T1:H:15; L: 19 T2-4:H:41; L: 28 H:(36/20); L:(23/34) H:(22/34); L:(7/50) H:(19/39); L:(15/42) H:(32/24); L:(36/21) H:(29/27); L:(33/24)   
Yasuoka* [17] 2008 Japan 113 5 years IHC Nuclear Score ≥ 5 (29/84) T1:H:11; L: 23 T2-4:H:18; L: 61 H:(13/16); L:(46/38) H:(7/22); L:(22/62) H:(7/22); L:(25/59) H:(18/11); L:(50/34) H:(17/12); L:(45/39)   
Woo [18] 2007 Korea 107 NA IHC Cytoplasm Score ≥ 4 (33/72) H:(0/7/18/8/0); L:(0/19/45/8/0) H:(21/12); L:(34/38)   H:(17/15); L:(30/34) H:(20/13); L:(41/27) H:(20/13); L:(38/28)   
Woo* [18] 2007 Korea 107 NA IHC Nuclear Score ≥ 4 (63/42) H:(0/16/37/10/0); L:(0/10/26/6/0) H:(39/24); L:(16/26)   H:(31/28); L:(16/21) H:(39/23); L:(22/17) H:(36/24); L:(22/17)   
Holm [19] 2007 USA 103 26 months Western blots Membrane and cytoplasm ≥6.6 F (41/62) H:(0/7/27/5/2); L:(0/23/32/7/0) H:(23/17); L:(33/30)       H:46% (19/41); L:70% (43/62)
Su [20] 2006 Taiwan 85 NA IHC Cytoplasm Score ≥ 3 (10/75) H:(0/2/8/0/0); L:(0/34/41/0/0) H:(5/2); L:(21/41) H:(1/9); L:(8/67) H:(6/3); L:(38/25) H:(7/3); L:(44/24) H:(3/7); L:(41/27)   
Su* [20] 2006 Taiwan 85 NA IHC Nuclear Score ≥ 3 (59/26) H:(0/27/32/0/0); L:(0/9/17/0/0) H:(15/30); L:(11/13) H:(6/53); L:(3/23) H:(30/19); L:(14/9) H:(33/20); L:(18/7) H:(29/24); L:(15/10)   
Salvucci [21] 2006 Canada 1699 68 months TMA Cytoplasm >50%, 30–50, <30 (121/590/986)   H:(40/66); M:(112/242); L:(422/460)   H:(108/705); M:(90/390) L:(32/57) H:(63/58); M:(436/154) L:(807/179) H:(19/102); M:(180/396); L:(359/597)   
Salvucci* [21] 2006 Canada 1697 69 months TMA Nuclear 30% (1161/538)   H:(514/527); L:(218/242)   H:(160/809); L:(70/343) H:(895/266); L:(412/126) H:(390/743); L:(166/353)   
Holm [22] 2009 USA 54 30 months Western blots Membrane and cytoplasm ≥6.6 F (19/35)        H:15% (3/19) L:40% (14/35) H:20% (4/19); L:55% (19/35)
  1. *Date from the same study of the previous line.